Some payers have already come out saying they'll need to see new guidelines from medical bodies and more data before they ease access to Eli Lilly and Boehringer Ingelheim's Jardiance, which recently posted a 14% reduction in the combined risk of heart attack, stroke and death from cardiovascular causes in high-risk Type 2 diabetes patients. But Credit Suisse analyst Vamil Divan is optimistic about the med's sales. He's raised his rating on Lilly to outperform, lifting his stock price target to $105--25% above Thursday's closing price of $83.77. Report